Drugs / EPP-AF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03024502 | Jan 2018 → Jan 2020 | vulvovaginal candidiasis | University of Sao Paulo | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT04800224 Comparator | Apr → Jul 2021 | COVID-19 | D'Or Institute for Research and Education | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EPP-AF | “The Use of Brazilian Green Propolis Extract (EPP-AF®) in Patients Affected by COVID-19” NCT04800224 ↗ |
| Known as | Propolis Standardized | “the objective of developing a mucoadhesive gel containing Propolis Standardized (EPP-AF®) for the treatment of vaginal candidiasis” NCT03024502 ↗ |
| Route | Oral | “Patients were allocated to receive an oral dose of 900 mg/day of EPP-AF® or placebo for 10 days.” PMID 37891178 ↗ Oct 2023 |